American Federation for Aging Research (AFAR)

COVID-19: Can the Science of Aging Move Us Forward?

Leading Experts to Discuss How Geroscience Insights and Promising Therapeutics Could Lessen the Severity of Pandemics, Age-Related Diseases

March 18, 2020 (New York, NY) – As the COVID-19 pandemic sweeps the nation and the world, the role that geroscience may play in boosting immunity in older adults and lessening the severity of age-related diseases will be explored by a panel of leading experts in the webinar, COVID-19: Can the Science of Aging Move Us Forward? The no-cost, one-hour webinar, intended for the scientific community and related science and health media, is scheduled for 1 PM EDT on Tuesday, March 24.

-- Register now  (Capacity is limited)--

Older adults and people with serious medical conditions, such as heart disease, diabetes, and lung disease, are at higher risk of getting very sick from COVID-19. Immune function declines as we age, but research has shown that these aging processes can be targeted. Promising therapeutics called “geroprotectors,” hold the potential to boost immunity and lessen the severity of infectious diseases like COVID-19.

Hosted by the American Federation for Aging Research (AFAR), the webinar will:

  • Provide an epidemiological update on COVID-19 in older adults and explain special health care considerations for older people;
  • Connect how the biological processes of aging influence inflammation and immune decline and how the severity of age-related diseases can be diminished through strategies that target the biology of aging; and
  • Present the latest information on promising geroprotectors, including metformin and mTOR inhibitors.

Presenters are:

  • Sean Leng, MD, PhD - Professor of Medicine, Johns Hopkins University School of Medicine, 2006 AFAR Beeson Scholar
  • Nir Barzilai, MD - AFAR Scientific Director; Director, Institute for Aging Research, Albert Einstein College of Medicine
  • George Kuchel, MD, FRCP, AGSF - Director and Chief of Geriatric Medicine, UConn Center on Aging, 

    University of Connecticut School of Medicine

  • Joan Mannick, MD - Co-Founder and Chief Medical Officer, resTORbio

“At a time when we face a complex public health crisis, it is vitally important to make sure the most up-to-date, reliable scientific information is available to people,” said AFAR Executive Director Stephanie Lederman. “As the leader in advancing research into the biology of aging, AFAR is deeply committed to sharing information not only on what’s happening today, but on what’s next related to the science that can help older adults live healthier and longer.”

### 

About AFAR. The American Federation for Aging Research (AFAR) is a national non-profit organization that supports and advances pioneering biomedical research that is revolutionizing how we live healthier and longer. For nearly four decades, AFAR has served as the field’s talent incubator, providing more than $181 million to more than 4,200 investigators at premier research institutions nationwide. A trusted leader and strategist, AFAR also works with public and private funders to steer high quality grant programs and interdisciplinary research networks.  AFAR-funded researchers are finding that modifying basic cellular processes can delay—or even prevent—many chronic diseases, often at the same time. They are discovering that it is never too late—or too early—to improve health. This groundbreaking science is paving the way for innovative new therapies that promise to improve and extend our quality of life—at any age. Learn more at www.afar.org or follow AFARorg on Twitter and Facebook.




Filters close

Showing results

110 of 4567
Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Released: 15-Jan-2021 11:20 AM EST
Will Covid-19 kill the high street once and for all?
University of Sheffield

The shift to home working during Covid-19, or ‘Zoomshock’, threatens the survival of local goods and services provided in city centres and business parks

14-Jan-2021 5:00 PM EST
AACI Partners With Federal Vaccine Panel to Promote Cancer Patient Health
Association of American Cancer Institutes (AACI)

AACI was invited last summer to join the Vaccine Consultation Panel (VCP) alongside other leading health and science organizations in the U.S. Through the VCP, AACI has received periodic updates on the development and distribution of COVID-19 vaccines and participated in efforts to educate the cancer center community and the general public on the importance of widespread vaccine uptake.

Released: 15-Jan-2021 8:55 AM EST
The First Dose of the Pfizer Vaccine Gives About 50% COVID Protection, Not 91% Claimed by Those Who Want to Speed Up Immunization
Newswise

The NEJM paper actually states that the efficacy between the first and second doses was found to be 52 percent when given 21 days apart. After the second dose, the efficacy raises to 95 percent.

Released: 15-Jan-2021 8:20 AM EST
Houston Methodist study finds males of all ages more affected by COVID-19 than females
Houston Methodist

A new Houston Methodist study found males are more likely to test positive for COVID-19, have complications and die from the virus than females, independent of age. The peer-reviewed observational study appears in PLOS ONE, a multidisciplinary journal published by the Public Library of Science.

Released: 15-Jan-2021 8:20 AM EST
NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19 Ivermectin is Now a Therapeutic Option for Doctors & Prescribers

Newswise: Studying and Treating COVID-19’s Long-Term Impact
Released: 14-Jan-2021 6:05 PM EST
Studying and Treating COVID-19’s Long-Term Impact
Rush University Medical Center

The CDC is funding a Rush-led effort in which 8 academic medical centers will track the clinical, physical and mental functioning -- including neuro-cognition and fatigue – of nearly 5000 COVID patients for two years to better assess the long-term outcomes of the disease.


Showing results

110 of 4567

close
1.36095